Project Grant R21CA318172
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $422K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
- Federal Grant Award Summary The University of Chicago received a $651,674 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2031. This five-year research initiative develops and validates a novel radioinducible plug-and-play Chimeric Antigen Receptor T-cell (CAR-T) system designed to enhance the efficacy of CAR-T immunotherapy combined with radiation therapy for solid tumors. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $518,151 Project Grant to the University of Chicago effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical advancement of NNMTI'960, a small-molecule inhibitor targeting Nicotinamide N-methyltransferase (NNMT) in the tumor microenvironment. The research investigates how NNMT inhibition reshapes tumor metabolism...
- Federal Project Grant Award Summary The University of Chicago received a $602,641 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on June 24, 2026, with a completion date of May 31, 2031. This research project investigates immune checkpoint receptor inhibitors (CPIs) and their associated immune-related adverse events (IRAEs), which affect up to 80% of CPI-treated cancer patients. The project will develop innovative mouse models...
- Federal Project Grant Award Summary The University of Chicago received a $372,628 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2028. This award supports research into spatiomolecular profiling of human cancer at scale, specifically focused on developing and advancing spatially resolved transcriptomics (ST) technologies for analyzing tumor...
- Federal Project Grant Award Summary The University of Chicago received a $588,289 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This award supports fundamental research on reprogramming T cell function through BCL-2 (B-cell lymphoma-2) family protein-protein disruption. The project investigates how BH3 (BCL-2 homology domain 3) mimetic therapeutics—drugs designed to induce cancer...
- Federal Project Grant Award Summary The University of Chicago received a $464,212 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on August 1, 2025, with a completion date of July 31, 2030. This five-year project supports research characterizing cancer susceptibility mechanisms associated with the TERT/CLPTM1L locus at chromosome 5p15.33, a highly pleiotropic genetic region linked to increased risk for over 15...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Chicago a $185,760 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, with a completion date of August 31, 2028. The award supports a research project titled "Targeting Glycerol Metabolism in Anti-Tumor Immunity," which investigates the mechanistic relationship between obesity-related metabolic changes and cancer progression, with particular focus on how...
- Grant Award Summary The University of Chicago received a $547,740 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026 through June 30, 2031. This award funds research defining the molecular mechanisms underlying RNA binding by the MLL1 (KMT2A) histone modification complex in acute myeloid leukemia (AML) etiology. The research challenges the current model that specific long noncoding RNAs (lncRNAs)...
- Grant Award Summary The National Cancer Institute awarded a Project Grant of $681,818 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on restoring anti-tumor immunity in chromosomally unstable tumors. Awarded on June 2, 2026, with a completion date of May 31, 2031, this research project addresses the mechanisms by which chromosomal instability (CIN) in solid tumors triggers...
- Federal Project Grant Award Summary The National Cancer Institute awarded $394,532 through its Cancer Treatment Research program (CFDA 93.395) to the Regents of the University of Minnesota on July 15, 2025, to support research investigating LAT1 (L-type amino acid transporter 1) as a novel therapeutic target in colorectal cancer. The research will be conducted through June 30, 2027, and focuses on developing innovative treatment approaches for microsatellite stable (MSS) tumors, which...